This new application proposes to investigate a newly identified mechanism of injury in shock which contributes to cellular and organ dysfunction. This PARS pathway of injury is triggered by oxidant-induced DNA single strand breaks. Recognized by the N-terminal domain of the nuclear enzyme poly (ADP-ribose) synthetase (PARS), oxidant-induced genetic damage activates the C-terminal domain of PARS, which catalyzes and energy consuming polymerization of ADP-ribose. Depletion of NAD by this process slows the rate of glycolysis and mitochondrial respiration, and thereby reduces ATP synthesis. In this proposal the applicant plans to test the central hypothesis that the PARS pathway contributes to organ injury and dysfunction in splanchnic I-R injury. 1. He will determine the whether pharmacological inhibition of PARS ameliorates cytotoxicity of cultured intestinal epithelial cells exposed to an in vitro oxidant stress (using nitric oxide, superoxide, peroxynitrite, or anoxia-reoxygenation). 2. He will establish whether PARS activation contributes to mucosal dysfunction in a rodent model of I-R injury. 3. He will establish whether PARS activation imitates a positive feedback cycle of mesenteric vascular injury by testing the effect of. PARS inhibitors on endothelial function in splanchnic I-R injury. The ultimate goal is to determine whether PARS inhibition represents a plausible strategy to prevent and treat splanchnic I-R injury.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM057407-03
Application #
6138653
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Somers, Scott D
Project Start
1998-01-01
Project End
2001-06-30
Budget Start
2000-01-01
Budget End
2001-06-30
Support Year
3
Fiscal Year
2000
Total Cost
$198,613
Indirect Cost
Name
Inotek Pharmaceuticals Corporation
Department
Type
DUNS #
090253571
City
Beverly
State
MA
Country
United States
Zip Code
01915
Liaudet, Lucas; Szabo, Csaba; Evgenov, Oleg V et al. (2003) Flagellin from gram-negative bacteria is a potent mediator of acute pulmonary inflammation in sepsis. Shock 19:131-7
Jagtap, Prakash; Soriano, Francisco Garcia; Virag, Laszlo et al. (2002) Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit Care Med 30:1071-82
Liaudet, Lucas; Murthy, Kanneganti G K; Mabley, Jon G et al. (2002) Comparison of inflammation, organ damage, and oxidant stress induced by Salmonella enterica serovar Muenchen flagellin and serovar Enteritidis lipopolysaccharide. Infect Immun 70:192-8
Eaves-Pyles, T; Murthy, K; Liaudet, L et al. (2001) Flagellin, a novel mediator of Salmonella-induced epithelial activation and systemic inflammation: I kappa B alpha degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction. J Immunol 166:1248-60
Liaudet, L; Szabo, A; Soriano, F G et al. (2000) Poly (ADP-ribose) synthetase mediates intestinal mucosal barrier dysfunction after mesenteric ischemia. Shock 14:134-41
Salzman, A L; Linn, S C; Szabo, C (2000) Progesterone inhibits inducible nitric oxide synthase mRNA expression in human intestinal epithelial cells. Int J Mol Med 6:209-16
Kennedy, M; Wilson, L; Szabo, C et al. (1999) 5-aminosalicylic acid inhibits iNOS transcription in human intestinal epithelial cells. Int J Mol Med 4:437-43
Eaves-Pyles, T; Szabo, C; Salzman, A L (1999) Bacterial invasion is not required for activation of NF-kappaB in enterocytes. Infect Immun 67:800-4
Wilson, L; Szabo, C; Salzman, A L (1999) Protein kinase C-dependent activation of NF-kappaB in enterocytes is independent of IkappaB degradation. Gastroenterology 117:106-14